Received Apr 30, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER LIVE (ZOSTAVAX) | MERCK & CO. INC. | UNK | — | — |
shingles with ocular involvement; diagnosed with shingles; This spontaneous report was received from a consumer and refers to herself, a female patient of unknown age. The patient's medical history , concurrent conditions and concomitant therapies were not reported. On 2015 (reported as approximately 10 years ago), the patient was vaccinated with Zoster Vaccine Live (ZOSTAVAX) for prophylaxis (strength, dose number, vaccination schedule, expiration date, and lot # were not reported). On early March of 2025 (also reported as approximately 10 years later), the patient developed shingles with ocular involvement (ophthalmic herpes zoster). Her symptoms began with unilateral, L-sided headache, for which her PCP obtained a head CT (results not provided). Her pain significantly worsened to the point where she presented to the emergency room and was diagnosed with shingles (Herpes zoster). Patient had a small rash on her left forehead, and involvement of her L eye (but not the retina, conflicting information) and was started on steroids, antivirals and pain medication (gabapentin). On an unspecified date in 2025, she was followed closely by XXX Hospital and her symptoms have now resolved aside from occasional mild headache (conflicting information). She denied any vision loss or chronic pain. Rash has resolved with slight scarring (recovered). The causal relationship between the events and suspect vaccine were unknown/not reported/not provided. As per internal review, the event ophthalmic herpes zoster was determined to be medically significant.